The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Intensive Care Medicine and Anesthesiology
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1431321
Methylene blue therapy in addition to standard treatment for acute-phase septic shock: a pilot randomized controlled trial
Provisionally accepted- 1 University of São Paulo, Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
- 2 René Rachou Institute, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Minas Gerais, Brazil
Purpose: Methylene blue (MB) has been used to increase blood pressure in patients with septic shock by acting on guanylate cyclase and nitric oxide synthase. Objective: To determine whether the administration of MB to patients in the initial phase of septic shock leads to a reduction in the use of vasopressors compared to the Control group. Methods:This was a 1:1 randomized clinical trial of two groups (MB and Control). Forty-two patients were included in the present study; 23 patients were allocated to the Control group, and 19 were randomized to the MB group. Both groups had access to standard treatment, consisting of fluid replacement, vasopressors, and antibiotic therapy. Patients received a loading dose of MB (3 mg/kg) and maintenance (0.5 mg/kg/h) for 48 hours.Vasopressor doses, laboratory test results, inflammatory and anti-inflammatory cytokine levels, and hemodynamic monitoring were recorded before the infusion of MB (T1) and after 20 minutes (T2), 2 hours (T3), 24 hours (T4), 48 hours after the infusion started (T5) and 24 hours after weaning (T6). Results: MB therapy was started together with the indication of vasopressin (VAS) as a second vasopressor. The MB group showed an immediate reduction in NOR dosage, an earlier reduction in VAS dosage, and higher IL-10 levels compared to the Control group. Conclusion: Early administration of MB in combination with standard treatment for septic shock might be reduce vasopressors dose.Continuous infusion of MB for 48 hours was considered safe and there was no adverse events. These results highlight the potential of MB as a safe adjuvant therapeutic option in the treatment of septic shock.Trial registration: Clinical registration: https://ensaiosclinicos.gov.br/rg/RBR-96584w4.
Keywords: Methylene Blue, septic shock, Lactate, Nitric Oxide, Cytokines, Vasopressors, Norepinephrine, vasopressin
Received: 11 May 2024; Accepted: 09 Aug 2024.
Copyright: © 2024 Luis Da Silva, Menegueti, Peres, Sepeda, Jordani, A.C. Mestriner, Petroski-Moraes, Brito-de-Sousa, Costa Rocha, Cruz, Donadel, Souza, Reis, Bellissimo-Rodrigues, Basile-Filho, Becari, Evor, Martins Filho and Auxiliadora-Martins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fabio Luis Da Silva, University of São Paulo, Ribeirão Preto, Ribeirão Preto, 14040-040, São Paulo, Brazil
Maria Auxiliadora-Martins, University of São Paulo, Ribeirão Preto, Ribeirão Preto, 14040-040, São Paulo, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.